8×8, Inc. (EGHT) EPS Estimated At $-0.03; Profile of 9 Analysts Covering Clovis Oncology (CLVS)

May 18, 2017 - By Henry Gaston

Analysts expect 8×8, Inc. (NASDAQ:EGHT) to report $-0.03 EPS on May, 25 after the close.They anticipate $0.00 EPS change or 0.00% from last quarter’s $-0.03 EPS. After having $-0.01 EPS previously, 8×8, Inc.’s analysts see 200.00% EPS growth. The stock decreased 5.42% or $0.75 during the last trading session, reaching $13.1. About shares traded. 8×8, Inc. (NASDAQ:EGHT) has risen 6.00% since April 18, 2017 and is uptrending. It has by 0.00% the S&P500.

Among 12 analysts covering Clovis Oncology (NASDAQ:CLVS), 9 have Buy rating, 1 Sell and 2 Hold. Therefore 75% are positive. Clovis Oncology had 33 analyst reports since September 10, 2015 according to SRatingsIntel. Chardan Capital Markets upgraded it to “Neutral” rating and $36 target in Tuesday, December 20 report. The stock of Clovis Oncology Inc (NASDAQ:CLVS) has “Buy” rating given on Friday, August 5 by Suntrust Robinson. Piper Jaffray upgraded the stock to “Overweight” rating in Thursday, January 26 report. The firm earned “Buy” rating on Friday, January 27 by Bank of America. PiperJaffray upgraded the shares of CLVS in report on Thursday, January 26 to “Overweight” rating. Chardan Capital Markets downgraded the stock to “Sell” rating in Friday, February 3 report. The firm has “Outperform” rating given on Wednesday, September 21 by Credit Suisse. The rating was maintained by Piper Jaffray on Monday, November 16 with “Neutral”. The rating was downgraded by JP Morgan to “Neutral” on Wednesday, April 13. Stifel Nicolaus maintained the stock with “Buy” rating in Wednesday, September 21 report. See Clovis Oncology Inc (NASDAQ:CLVS) latest ratings:

17/05/2017 Broker: JP Morgan Old Rating: Neutral New Rating: Overweight Upgrade
03/02/2017 Broker: Chardan Capital Markets Old Rating: Neutral New Rating: Sell New Target: $36 Downgrade
27/01/2017 Broker: Bank of America Rating: Buy New Target: $74.00 Initiate
26/01/2017 Broker: PiperJaffray Old Rating: Neutral New Rating: Overweight Upgrade
26/01/2017 Broker: Piper Jaffray Old Rating: Neutral New Rating: Overweight Upgrade
23/01/2017 Broker: Stifel Nicolaus Rating: Buy Old Target: $52 New Target: $86 Maintain
13/01/2017 Broker: Morgan Stanley Rating: Overweight Initiate
21/12/2016 Broker: WallachBeth Capital Rating: Hold Old Target: $22 New Target: $49 Maintain
20/12/2016 Broker: Chardan Capital Markets Old Rating: Sell New Rating: Neutral Old Target: $15 New Target: $36 Upgrade

Since March 15, 2017, it had 0 insider purchases, and 2 sales for $343,140 activity. IVERS-READ GILLIAN C had sold 3,000 shares worth $200,970.

Investors sentiment decreased to 1.03 in Q4 2016. Its down 0.97, from 2 in 2016Q3. It is negative, as 30 investors sold Clovis Oncology Inc shares while 48 reduced holdings. 38 funds opened positions while 42 raised stakes. 35.69 million shares or 2.51% less from 36.61 million shares in 2016Q3 were reported. Moreover, Columbia Wanger Asset Mngmt Ltd Liability Company has 0.12% invested in Clovis Oncology Inc (NASDAQ:CLVS) for 189,958 shares. Alliancebernstein L P owns 46,040 shares. Panagora Asset Mngmt Inc reported 104 shares. Perceptive Ltd reported 167,754 shares or 0.53% of all its holdings. State Street accumulated 2.14M shares or 0.01% of the stock. Blackrock Inc invested in 2,565 shares or 0% of the stock. California Public Employees Retirement System, a California-based fund reported 24,900 shares. Cornerstone Management Holdings Ltd Company holds 0% or 1,200 shares in its portfolio. Td Asset Mngmt Inc reported 0% of its portfolio in Clovis Oncology Inc (NASDAQ:CLVS). Invesco Ltd invested 0% of its portfolio in Clovis Oncology Inc (NASDAQ:CLVS). Marshall Wace Ltd Liability Partnership owns 0.02% invested in Clovis Oncology Inc (NASDAQ:CLVS) for 83,014 shares. The United Kingdom-based Pictet Asset Mgmt Ltd has invested 0.03% in Clovis Oncology Inc (NASDAQ:CLVS). Manufacturers Life Ins The has 0% invested in Clovis Oncology Inc (NASDAQ:CLVS). Cam A S accumulated 325,505 shares. Principal Gp Inc Inc stated it has 5,898 shares or 0% of all its holdings.

The stock increased 1.90% or $0.94 during the last trading session, reaching $50.5. About shares traded. Clovis Oncology Inc (NASDAQ:CLVS) has risen 6.00% since April 18, 2017 and is uptrending. It has by 0.00% the S&P500.

Clovis Oncology, Inc. is a biopharmaceutical firm focused on acquiring, developing and commercializing anti-cancer agents in the United States, Europe and other international markets. The company has market cap of $2.31 billion. The Company’s product candidates include Rociletinib, Rubraca and Lucitanib. It currently has negative earnings. Rucaparib is an oral, small molecule poly adenosine diphosphate (ADP)-ribose polymerase (PARP) inhibitor of PARP1, PARP2 and PARP3 approved as a monotherapy for the treatment of patients with deleterious breast cancer (BRCA) (human genes associated with the repair of damaged deoxyribonucleic acid (DNA)) mutation (germline and/or somatic) associated advanced ovarian cancer.

8×8, Inc. provides cloud-based, enterprise-class software solutions. The company has market cap of $1.23 billion. The Company’s solutions are delivered through Software as a Service business model. It currently has negative earnings. The Company’s divisions include Americas and Europe.

Since January 31, 2017, it had 0 buys, and 3 selling transactions for $2.07 million activity. 25,000 shares were sold by SALZMAN ERIC, worth $385,318 on Wednesday, February 8. 100,000 shares valued at $1.56M were sold by MARTIN BRYAN R on Friday, February 10. Hakeman Darren J. sold 7,500 shares worth $118,915.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our daily email newsletter.

Free Email Newsletter

Enter your email address below to get the latest news and analysts' ratings for your stocks with our free daily email newsletter: